Skip to main content

Table 1 Demographic information and disease-specific characteristics for the STN-DBS PD patients

From: Low-frequency STN-DBS provides acute gait improvements in Parkinson’s disease: a double-blinded randomised cross-over feasibility trial

  n = 14
Demographics  
Gender (male)a 12.0 (85.7)
Age (years) 69.6 (7.5)
Height (m) 1.8 (0.1)
Mass (kg) 81.3 (15.1)
Falls history and fear of falls  
Retrospective fallera 7.0 (50.0)
ABC-6 (max. score = 100) 53.8 (23.6)
Neurological examination
Disease duration (years) 12.0 (6.2)
MDS-UPDRS III 32.7 (10.7)
Experience freezing of gaita 5.0 (35.7)
New freezing of gait questionnaire 19.8 (5.8)
8-Item Parkinson’s disease questionnaire 27.7 (15.9)
No PD medicationsa 7.0 (50.0)
Levodopa dose (mg/day) 271.5 (115.0)
Dopamine agonistsa 4.0 (28.6)
Monoamine oxidase type B inhibitorsa 0.0 (0.0)
Catechol-o-methyl transferase inhibitorsa 0.0 (0.0)
DBS information  
Time since STN-DBS (years) 4.0 (2.4)
Euclidean distanceb 2.36 (0.32–5.17)
X distance (negative = medial)b − 0.90 (− 3.17–1.72)
Y distance (negative = posterior)b − 0.35 (− 1.80–3.45)
Z distance (negative = inferior)b − 0.74 (− 4.33–2.68)
  1. Data represent mean (± 1 standard deviation), absolute numbers (percentage of sample)a or mean (range)b
  2. ABC-6 6-item Activities-specific Balance Confidence scale, MDS-UPDRS III motor subscale of the Movement Disorders Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale